Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T

1H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with…

Continue ReadingAllogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
Read more about the article First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Large B-Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy: The Pivotal, Randomized, Open-Label Phase 2 ALPHA3 Study

First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Large B-Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy: The Pivotal, Randomized, Open-Label Phase 2 ALPHA3 Study

Continue ReadingFirst-Line Consolidation With Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Large B-Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy: The Pivotal, Randomized, Open-Label Phase 2 ALPHA3 Study

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel) Decision Reconfirms Allogene’s Expanded Sub-License Covering EU and UK Rights with Options for Japan and China , Clearing the Path…

Continue ReadingAllogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis